Loading organizations...
§ Private Profile · Cambridge, MA, USA
AI models developer providing open-source and commercial products for biomolecular structure prediction and drug design in pharma and biotech.
Boltz is a Cambridge, Massachusetts-based public-benefit corporation that develops open-source artificial intelligence models for biomolecular structure prediction, de-novo protein design, and small-molecule hit discovery. The company provides commercially usable alternatives to AlphaFold3, serving an active user base of over 100,000 scientists across thousands of biotechnology firms and every top twenty pharmaceutical company. Through its Boltz Lab platform, the organization offers both freely available models and commercial infrastructure to accelerate programmable biology, recently establishing a strategic partnership with Pfizer. The enterprise has raised $28 million in Series Seed funding backed by lead investors Andreessen Horowitz, Amplify Partners, and Zetta Venture Partners, alongside strategic angel investors including Hugging Face chief executive officer Clement Delangue. Originating as a research initiative at the Massachusetts Institute of Technology, Boltz was founded in 2026 by Gabriele Corso, Jeremy Wohlwend, and Saro Passaro.
Boltz has raised $28.0M across 1 funding round.
Boltz has raised $28.0M in total across 1 funding round.
Boltz has raised $28.0M across 1 funding round. Most recently, it raised $28.0M Seed in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 12, 2026 | $28M Seed | Amplify Partners, Andreessen Horowitz, Zetta Venture Partners | — | Announced |
Boltz has raised $28.0M in total across 1 funding round.
Boltz's investors include Amplify Partners, Andreessen Horowitz, Zetta Venture Partners.